Search results for "LYMPHOCYTE"

showing 10 items of 2280 documents

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity

2008

Despite as yet limited clinical effectiveness, dendritic cell (DC)-based immunotherapy remains a promising approach for the treatment of cancer, but requires further improvement in its immunostimulatory effectiveness. Potent anti-tumor immunity often depends on the induction of type 1 (T(H)1) immune responses. Therefore, we combined different DC maturation stimuli that are known to induce T(H)1 immunity [anti-CD40, interleukin (IL)-12, IL-18], with the aim to trigger a T(H)1 driven anti-tumor CTL response. When compared with untreated DC or DC treated with anti-CD40 alone, DC matured with anti-CD40 plus IL-12 and IL-18 expressed significantly more IFN-gamma and IL-12, induced enhanced CD8(+…

medicine.medical_treatmentAntineoplastic AgentsDermatologyCD8-Positive T-LymphocytesModels BiologicalBiochemistryMiceImmune systemAntigens NeoplasmmedicineAnimalsCD40 AntigensAntigen-presenting cellMolecular BiologyMice Inbred BALB Cbusiness.industryInterleukin-18InterleukinDendritic CellsImmunotherapyDendritic cellTh1 CellsInterleukin-12Tumor antigenMice Inbred C57BLImmune SystemImmunologyInterleukin 12ImmunotherapybusinessCD8Experimental Dermatology
researchProduct

Influence of extracellular matrix proteins on the development of cultured human dendritic cells.

1998

The development of dendritic cells (DC) is still only partly understood. Recently established culture systems using CD34+ cells or monocytes as precursor cells for the generation of DC indicate the necessity of pro-inflammatory cytokines for their development. In vivo the contact to other cells or to the proteins of the extracellular matrix might also be essential for their development. In our experiments we used granulocyte-macrophage colony-stimulating factor- and IL-4-treated human monocytes as precursor cells to investigate the interaction of DC at different maturation stages with the matrix proteins fibronectin, collagen type I and collagen type IV. We demonstrate a strong beta1-integr…

medicine.medical_treatmentCellular differentiationImmunologyCD34Cell CommunicationMatrix (biology)BiologyMonocytesExtracellular matrixPrecursor cellmedicineCell AdhesionImmunology and AllergyHumansCells CulturedExtracellular Matrix ProteinsTumor Necrosis Factor-alphaIntegrin beta1Cell DifferentiationDendritic cellDendritic CellsCell biologyFibronectinsUp-RegulationFibronectinCytokineAntigens Surfacebiology.proteinCollagenLymphocyte Culture Test MixedEuropean journal of immunology
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

2002

Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was …

medicine.medical_treatmentGenetic VectorsEpitopes T-LymphocyteMice TransgenicPilot ProjectsHuman leukocyte antigenBiologyMajor histocompatibility complexCancer VaccinesEpitopeAdenoviridaeMiceImmune systemCancer immunotherapyAntigenSpecies SpecificityNeoplasmsHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansTreatment FailureMolecular BiologyT lymphocyteGenetic TherapyGenes p53Self ToleranceImmunologybiology.proteinMolecular MedicineTumor Suppressor Protein p53T-Lymphocytes CytotoxicGene therapy
researchProduct

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation

2014

Graft-versus-host disease (GVHD) is a frequent life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT) and induced by donor-derived T cells that become activated by host antigen-presenting cells. To address the relevance of host dendritic cell (DC) populations in this disease, we used mouse strains deficient in CD11c(+) or CD8α(+) DC populations in a model of acute GVHD where bone marrow and T cells from BALB/c donors were transplanted into C57BL/6 hosts. Surprisingly, a strong increase in GVHD-related mortality was observed in the absence of CD11c(+) cells. Likewise, Batf3-deficient (Batf3(-/-)) mice that lack CD8α(+) DCs also displayed a strongly incr…

medicine.medical_treatmentGraft vs Host DiseasePriming (immunology)CD11cHematopoietic stem cell transplantationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationCD8-Positive T-LymphocytesBiologyGraft-versus-host diseaseDendritic cellsMiceimmune system diseasesBATF3medicineAnimalsTransplantation HomologousBone Marrow TransplantationMice Inbred BALB CTransplantationPeripheral toleranceHematologyDendritic cellmedicine.diseaseMice Inbred C57BLsurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureImmunologyBone marrowCD8Biology of Blood and Marrow Transplantation
researchProduct

Transcription factors controlling development and function of innate lymphoid cells.

2014

Abstract Innate lymphoid cells (ILCs) are a heterogeneous group of lymphocytes, which play an important role in tissue homeostasis at epithelial surfaces. They are scarce in spleen and lymph nodes, but substantial numbers can be found in the intestinal mucosa even at steady state. There, they represent the first line of defence against invading pathogens and contribute to lymphorganogenesis, tissue repair and, when inappropriately activated, immune pathology. Lineage-specific development, function and maintenance of these cells depend on a restricted set of transcription factors that partially emerged as a result of diversification and selection during vertebrate evolution. The differential…

medicine.medical_treatmentImmunologyBiologyLymphocyte ActivationIntestinal mucosaRAR-related orphan receptor gammamedicineTranscriptional regulationImmunology and AllergyAnimalsHomeostasisHumansCell LineageLymphopoiesisLymphocytesIntestinal MucosaTranscription factorTissue homeostasisInnate lymphoid cellGene Expression Regulation DevelopmentalCell DifferentiationGeneral MedicineBiological EvolutionImmunity InnateCytokineImmunologyHost-Pathogen InteractionsCytokinesInterleukin Receptor Common gamma SubunitTranscription FactorsInternational immunology
researchProduct

IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1

2007

IL-27 is an IL-12-related cytokine frequently present at sites of inflammation that can promote both anti- and pro-inflammatory immune responses. Here, we have analyzed the mechanisms how IL-27 may drive such divergent immune responses. While IL-27 suppressed the development of proinflammatory Th17 cells, a novel role for this cytokine in inhibiting the development of anti-inflammatory, inducible regulatory T cells (iTreg) was identified. In fact, IL-27 suppressed the development of adaptive, TGF-beta-induced Forkhead box transcription factor p3-positive (Foxp3(+)) Treg. Whereas the blockade of Th17 development was dependent on the transcription factor STAT1, the suppression of iTreg develo…

medicine.medical_treatmentImmunologyMice Transgenicchemical and pharmacologic phenomenaInflammationBiologyT-Lymphocytes RegulatoryProinflammatory cytokineMiceImmune systemT-Lymphocyte SubsetsmedicineAnimalsImmunology and AllergySTAT1IL-2 receptorTranscription factorInterleukinsFOXP3Forkhead Transcription FactorsFlow CytometryCoculture TechniquesCell biologySTAT1 Transcription FactorCytokineImmunologybiology.proteinmedicine.symptomEuropean Journal of Immunology
researchProduct

Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.

2014

Multivalent synthetic vaccines were obtained by solid-phase synthesis of tumor-associated MUC1 glycopeptide antigens and their coupling to a Pam3 Cys lipopeptide through click reactions. These vaccines elicited immune responses in mice without the use of any external adjuvant. The vaccine containing four copies of a MUC1 sialyl-TN antigen showed a significant cluster effect. It induced in mice prevailing IgG2a antibodies, which bind to MCF-7 breast tumor cells and initiate the killing of these tumor cells by activation of the complement-dependent cytotoxicity complex.

medicine.medical_treatmentLipoproteinsEpitopes T-LymphocyteApoptosisCancer VaccinesCatalysisAntibodieschemistry.chemical_compoundMiceImmune systemAntigenmedicineAnimalsHumansAmino Acid Sequenceskin and connective tissue diseasesCytotoxicityMUC1Mice Inbred BALB CbiologyMucin-1GlycopeptidesLipopeptideGeneral ChemistryCombinatorial chemistryGlycopeptidechemistrybiology.proteinCancer researchMCF-7 CellsClick ChemistryRabbitsAntibodyAdjuvantAngewandte Chemie (International ed. in English)
researchProduct

Immune Modulating Effects of NKT Cells in a Physiologically Low Dose Leishmania major Infection Model after αGalCer Analog PBS57 Stimulation

2014

Leishmaniasis is a parasitic infection affecting ∼12 million people worldwide, mostly in developing countries. Treatment options are limited and no effective vaccines exist to date. Natural Killer T (NKT) cells are a conserved innate-like lymphocyte population with immunomodulating effects in various settings. A number of reports state a role of NKT cells in different models of Leishmania infection. Here, we investigated the effect of NKT cells in a physiologically relevant, intradermal low dose infection model. After inoculation of 103 infectious-stage L. major, comparable numbers of skin-immigrating NKT cells in both susceptible BALB/c mice and resistant C57BL/6 mice were noted. Compared …

medicine.medical_treatmentLymphocyteMedizinPathogenesisNK cellsProtozoologyPathology and Laboratory MedicineCellular typesMedicine and Health SciencesLymphoid OrgansLeishmania majorImmune ResponseLeishmania majorSkinProtozoansMice Inbred BALB Ceducation.field_of_studybiologylcsh:Public aspects of medicineNatural killer T cellInfectious Diseasesmedicine.anatomical_structureCytokineMedical MicrobiologyHost-Pathogen InteractionsWhite blood cellsCytokinesAnatomyResearch ArticleCell biologyBlood cellslcsh:Arctic medicine. Tropical medicinelcsh:RC955-962Immune CellsImmunologyPopulationT cellsLeishmaniasis CutaneousGalactosylceramidesSpleenImmunopathologyMicrobiologyLymphatic SystemImmunomodulationImmune ActivationImmune systemImmunityMicrobial ControlmedicineAnimalsImmunologic FactorseducationImmunity to InfectionsMicrobial PathogensBiology and life sciencesImmunityOrganismsPublic Health Environmental and Occupational HealthImmunoregulationlcsh:RA1-1270Molecular Developmentbiology.organism_classificationAcquired Immune SystemParasitic ProtozoansMice Inbred C57BLDisease Models AnimalAnimal cellsImmune SystemImmunologyNatural Killer T-CellsClinical ImmunologyParasitologyDevelopmental Biology
researchProduct